<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01856790</url>
  </required_header>
  <id_info>
    <org_study_id>1211011156</org_study_id>
    <nct_id>NCT01856790</nct_id>
  </id_info>
  <brief_title>Effect of Liraglutide on Automated Closed-loop Glucose Control in Type 1 Diabetes</brief_title>
  <official_title>Effect of Liraglutide on Automated Closed-loop Glucose Control in Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jennifer Sherr</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Juvenile Diabetes Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      &quot;Closed loop artificial pancreas&quot; systems have been under development for the control of
      blood sugars in those living with diabetes. These systems consist of a continuous glucose
      sensor, which sends a signal to a computer program that automatically determines how much
      insulin to give. The computer program then tells an insulin pump to deliver the insulin.
      While such systems have been tested under a number of conditions, post-meal blood sugars are
      difficult to control. This study is designed to see if liraglutide, a glucagon like peptide
      receptor agonist, can help minimize the post meal blood sugar spikes in subjects with type 1
      diabetes while they are on a closed loop system.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Open-label, crossover study comparing the peak post-prandial glucose levels and the
      incremental post-prandial glucose area under the curve (AUC) during closed loop (CL) control
      alone and during CL control with liraglutide in an inpatient research setting. Data generated
      during outpatient baseline evaluation and liraglutide dose titration phases of the study will
      be compared to assess the short-term efficacy of this agent during open-loop continuous
      subcutaneous insulin infusion (CSII) pump treatment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Peak Post-prandial Venous Glucose Levels</measure>
    <time_frame>48 hours</time_frame>
    <description>peak post-prandial venous glucose levels obtained after breakfast, lunch, and dinner between closed loop (CL) alone and CL + liraglutide</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the Incremental Meal-related Glucose Area Under Curve (AUC)</measure>
    <time_frame>5-hour post prandial period after breakfast, lunch, and dinner</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Mean 24-hour Glucose Levels</measure>
    <time_frame>24- hours</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Mean Time to Peak Post-meal Glucose Value</measure>
    <time_frame>5- hour postprandial period</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Mean Daytime Glucose Levels</measure>
    <time_frame>8a.m.-11p.m.</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Incremental Glucagon Peak</measure>
    <time_frame>5 hours</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>AUC Plasma Glucagon During MMTT</measure>
    <time_frame>2 hours</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Differences in Daily Insulin Requirements</measure>
    <time_frame>24 hours</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Prandial Insulin Delivery During Closed Loop Therapy</measure>
    <time_frame>Average of the 5-hour post prandial period for breakfast, lunch, dinner combined</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Mean Nocturnal Glucose Levels</measure>
    <time_frame>11p.m.-6a.m.</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>Closed Loop Insulin Delivery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Each participant recruited into the study will undergo two inpatient closed loop admissions.
The first admission will be utilizing closed loop control alone, using the Medtronic external Physiological Insulin Delivery (ePID) algorithm. The ePID controller uses a proportional-integral-derivative algorithm modified to include insulin feedback.
Following the first closed loop admission, each participant is initiated on adjunctive once daily liraglutide therapy. They undergo a 3-4 week dose titration period.
Participants are then admitted for a second closed loop admission to assess the combined effects of closed loop control with adjunctive once daily liraglutide therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>ePID closed loop system</intervention_name>
    <description>Insulin pump controlled by closed loop unit and algorithm</description>
    <arm_group_label>Closed Loop Insulin Delivery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liraglutide</intervention_name>
    <description>Liraglutide is a long-acting analog of human glucagon like peptide-1 (GLP-1) that works as a GLP-1 receptor agonist</description>
    <arm_group_label>Closed Loop Insulin Delivery</arm_group_label>
    <other_name>Victoza</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. age 18-40 years

          2. clinical diagnosis of Type 1 diabetes (T1D) (formal antibody and/or genetic testing
             will not be required)

          3. duration of T1D ≥ 1 year

          4. HbA1c ≤ 9 %

          5. Treated with CSII for at least 3 months

          6. Body weight &gt; 50 kg (to accommodate phlebotomy)

          7. Be in good general health without other medical or psychiatric illnesses that would,
             in the judgment of the investigator, interfere with subject safety or study conduct

        Exclusion Criteria:

          1. Insulin resistant (defined as requiring &gt; 1.5 units/kg/day at time of study
             enrollment)

          2. Presence of any medical or psychiatric disorder that may interfere with subject safety
             or study conduct

          3. Use of any medications (besides insulin) known to blood glucose levels, including oral
             or other systemic glucocorticoid therapy. Inhaled, intranasal, or rectal
             corticosteroid use is allowed along as not given within 4 weeks of admission to the
             hospital research unit (HRU). Use of topical glucocorticoids is allowable as long as
             affected skin area does not overlap with study device sites. Subjects using herbal
             supplements will be excluded, due to the unknown effects of these supplements on
             glucose control

          4. History of hypoglycemic seizure within last 3 months

          5. Anemic (low hematocrit), evidence of renal insufficiency (elevated serum creatinine,
             BUN) or elevated liver function tests.

          6. Female subjects who are pregnant, lactating, or unwilling to be tested for pregnancy

          7. History of celiac disease gastroparesis, gastroesophageal reflux disease (GERD),
             disorder of gastric emptying, or disorder of intestinal motility

          8. Taking a medication known to affect gastric motility

          9. History of pancreatitis, gallstones, alcoholism or high triglyceride levels

         10. Personal or family history of thyroid cancer or multiple endocrine neoplasia type 2
             (MEN2)

         11. Subjects unable to give consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer Sherr, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale University School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>May 14, 2013</study_first_submitted>
  <study_first_submitted_qc>May 14, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 17, 2013</study_first_posted>
  <results_first_submitted>April 18, 2016</results_first_submitted>
  <results_first_submitted_qc>January 28, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 30, 2020</results_first_posted>
  <last_update_submitted>January 28, 2020</last_update_submitted>
  <last_update_submitted_qc>January 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Yale University</investigator_affiliation>
    <investigator_full_name>Jennifer Sherr</investigator_full_name>
    <investigator_title>Instructor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>All Study Participants</title>
          <description>Each participant recruited into the study will undergo two inpatient closed loop admissions.
The first admission will be utilizing closed loop control alone, using the Medtronic external Physiological Insulin Delivery (ePID) algorithm. The ePID controller uses a proportional-integral-derivative algorithm modified to include insulin feedback.
Following the first closed loop admission, each participant is initiated on adjunctive once daily liraglutide therapy. They undergo a 3-4 week dose titration period.
Participants are then admitted for a second closed loop admission to assess the combined effects of closed loop control with adjunctive once daily liraglutide therapy.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Closed Loop Control</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Closed Loop Control + Liraglutide</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Baseline Subject Characteristics</title>
          <description>Each participant recruited into the study will undergo two inpatient closed loop admissions.
The first admission will be utilizing closed loop control alone, using the Medtronic external Physiological Insulin Delivery (ePID) algorithm. The ePID controller uses a proportional-integral-derivative algorithm modified to include insulin feedback.
Following the first closed loop admission, each participant is initiated on adjunctive once daily liraglutide therapy. They undergo a 3-4 week dose titration period.
Participants are then admitted for a second closed loop admission to assess the combined effects of closed loop control with adjunctive once daily liraglutide therapy.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22" spread="3.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Peak Post-prandial Venous Glucose Levels</title>
        <description>peak post-prandial venous glucose levels obtained after breakfast, lunch, and dinner between closed loop (CL) alone and CL + liraglutide</description>
        <time_frame>48 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Closed Loop Insulin Delivery</title>
            <description>Each participant recruited into the study will undergo two inpatient closed loop admissions.
The first admission will be utilizing closed loop control alone, using the Medtronic external Physiological Insulin Delivery (ePID) algorithm. The ePID controller uses a proportional-integral-derivative algorithm modified to include insulin feedback.</description>
          </group>
          <group group_id="O2">
            <title>Closed Loop + Liraglutide</title>
            <description>Following the first closed loop admission, each participant is initiated on adjunctive once daily liraglutide therapy. They undergo a 3-4 week dose titration period.
Participants are then admitted for a second closed loop admission to assess the combined effects of closed loop control with adjunctive once daily liraglutide therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Post-prandial Venous Glucose Levels</title>
          <description>peak post-prandial venous glucose levels obtained after breakfast, lunch, and dinner between closed loop (CL) alone and CL + liraglutide</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98" spread="24"/>
                    <measurement group_id="O2" value="76" spread="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.05</p_value>
            <method>Wilcoxon Matched Pairs signed rank tests</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>the Incremental Meal-related Glucose Area Under Curve (AUC)</title>
        <time_frame>5-hour post prandial period after breakfast, lunch, and dinner</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Closed Loop Insulin Delivery</title>
            <description>Each participant recruited into the study will undergo two inpatient closed loop admissions.
The first admission will be utilizing closed loop control alone, using the Medtronic external Physiological Insulin Delivery (ePID) algorithm. The ePID controller uses a proportional-integral-derivative algorithm modified to include insulin feedback.</description>
          </group>
          <group group_id="O2">
            <title>Closed Loop + Liraglutide</title>
            <description>Following the first closed loop admission, each participant is initiated on adjunctive once daily liraglutide therapy. They undergo a 3-4 week dose titration period.
Participants are then admitted for a second closed loop admission to assess the combined effects of closed loop control with adjunctive once daily liraglutide therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>the Incremental Meal-related Glucose Area Under Curve (AUC)</title>
          <units>mg*hr/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="789" spread="176"/>
                    <measurement group_id="O2" value="500" spread="151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Wilcoxon Matched Pairs signed rank tests</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Mean 24-hour Glucose Levels</title>
        <time_frame>24- hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Closed Loop Insulin Delivery</title>
            <description>Following the first closed loop admission, each participant is initiated on adjunctive once daily liraglutide therapy. They undergo a 3-4 week dose titration period.
Participants are then admitted for a second closed loop admission to assess the combined effects of closed loop control with adjunctive once daily liraglutide therapy.</description>
          </group>
          <group group_id="O2">
            <title>Closed Loop + Liraglutide</title>
            <description>Following the first closed loop admission, each participant is initiated on adjunctive once daily liraglutide therapy. They undergo a 3-4 week dose titration period.
Participants are then admitted for a second closed loop admission to assess the combined effects of closed loop control with adjunctive once daily liraglutide therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean 24-hour Glucose Levels</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130" spread="51"/>
                    <measurement group_id="O2" value="135" spread="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Mean Time to Peak Post-meal Glucose Value</title>
        <time_frame>5- hour postprandial period</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Closed Loop Insulin Delivery</title>
            <description>Each participant recruited into the study will undergo two inpatient closed loop admissions.
The first admission will be utilizing closed loop control alone, using the Medtronic external Physiological Insulin Delivery (ePID) algorithm. The ePID controller uses a proportional-integral-derivative algorithm modified to include insulin feedback.</description>
          </group>
          <group group_id="O2">
            <title>Closed Loop + Liraglutide</title>
            <description>Following the first closed loop admission, each participant is initiated on adjunctive once daily liraglutide therapy. They undergo a 3-4 week dose titration period.
Participants are then admitted for a second closed loop admission to assess the combined effects of closed loop control with adjunctive once daily liraglutide therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Time to Peak Post-meal Glucose Value</title>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="0.5"/>
                    <measurement group_id="O2" value="1.8" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.97</p_value>
            <method>Wilcoxon Matched Pairs signed rank tests</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Mean Daytime Glucose Levels</title>
        <time_frame>8a.m.-11p.m.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ePID Closed Loop System Without Liraglutide</title>
            <description>ePID closed loop system alone
ePID closed loop system: Insulin pump controlled by closed loop unit and algorithm</description>
          </group>
          <group group_id="O2">
            <title>ePID Closed Loop System With Liraglutide</title>
            <description>liraglutide + ePID closed loop system
ePID closed loop system: Insulin pump controlled by closed loop unit and algorithm
liraglutide: Liraglutide is a long-acting analog of human glucagon-like peptide 1 (GLP-1) that works as a GLP-1 receptor agonist</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Daytime Glucose Levels</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="143" spread="55"/>
                    <measurement group_id="O2" value="146" spread="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Incremental Glucagon Peak</title>
        <time_frame>5 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Closed Loop Insulin Delivery</title>
            <description>Each participant recruited into the study will undergo two inpatient closed loop admissions.
The first admission will be utilizing closed loop control alone, using the Medtronic external Physiological Insulin Delivery (ePID) algorithm. The ePID controller uses a proportional-integral-derivative algorithm modified to include insulin feedback.</description>
          </group>
          <group group_id="O2">
            <title>Closed Loop + Liraglutide</title>
            <description>Following the first closed loop admission, each participant is initiated on adjunctive once daily liraglutide therapy. They undergo a 3-4 week dose titration period.
Participants are then admitted for a second closed loop admission to assess the combined effects of closed loop control with adjunctive once daily liraglutide therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Incremental Glucagon Peak</title>
          <units>pg/mL/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29" spread="16"/>
                    <measurement group_id="O2" value="35" spread="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>AUC Plasma Glucagon During MMTT</title>
        <time_frame>2 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Closed Loop Insulin Delivery</title>
            <description>Each participant recruited into the study will undergo two inpatient closed loop admissions.
The first admission will be utilizing closed loop control alone, using the Medtronic external Physiological Insulin Delivery (ePID) algorithm. The ePID controller uses a proportional-integral-derivative algorithm modified to include insulin feedback.</description>
          </group>
          <group group_id="O2">
            <title>Closed Loop + Liraglutide</title>
            <description>Following the first closed loop admission, each participant is initiated on adjunctive once daily liraglutide therapy. They undergo a 3-4 week dose titration period.
Participants are then admitted for a second closed loop admission to assess the combined effects of closed loop control with adjunctive once daily liraglutide therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>AUC Plasma Glucagon During MMTT</title>
          <units>pg*min/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1904" spread="651"/>
                    <measurement group_id="O2" value="1801" spread="906"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Differences in Daily Insulin Requirements</title>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Pre-Liraglutide Treatment</title>
            <description>Baseline characteristics prior to liraglutide therapy</description>
          </group>
          <group group_id="O2">
            <title>Post-Liraglutide Treatment</title>
            <description>Characteristics following 3 week outpatient dose titration phase of liraglutide</description>
          </group>
        </group_list>
        <measure>
          <title>Differences in Daily Insulin Requirements</title>
          <units>units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.5" spread="14"/>
                    <measurement group_id="O2" value="37.5" spread="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>.001</p_value>
            <method>Wilcoxon Matched Pairs signed rank tests</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Prandial Insulin Delivery During Closed Loop Therapy</title>
        <time_frame>Average of the 5-hour post prandial period for breakfast, lunch, dinner combined</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Closed Loop Insulin Delivery</title>
            <description>Each participant recruited into the study will undergo two inpatient closed loop admissions.
The first admission will be utilizing closed loop control alone, using the Medtronic external Physiological Insulin Delivery (ePID) algorithm. The ePID controller uses a proportional-integral-derivative algorithm modified to include insulin feedback.</description>
          </group>
          <group group_id="O2">
            <title>Closed Loop + Liraglutide</title>
            <description>Following the first closed loop admission, each participant is initiated on adjunctive once daily liraglutide therapy. They undergo a 3-4 week dose titration period.
Participants are then admitted for a second closed loop admission to assess the combined effects of closed loop control with adjunctive once daily liraglutide therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Prandial Insulin Delivery During Closed Loop Therapy</title>
          <units>units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.6" spread="8.4"/>
                    <measurement group_id="O2" value="16.3" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other (legacy)</non_inferiority_type>
            <p_value>0.005</p_value>
            <method>Wilcoxon Matched Pairs signed rank tests</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Mean Nocturnal Glucose Levels</title>
        <time_frame>11p.m.-6a.m.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Closed Loop Insulin Delivery</title>
            <description>Each participant recruited into the study will undergo two inpatient closed loop admissions.
The first admission will be utilizing closed loop control alone, using the Medtronic external Physiological Insulin Delivery (ePID) algorithm. The ePID controller uses a proportional-integral-derivative algorithm modified to include insulin feedback.</description>
          </group>
          <group group_id="O2">
            <title>Closed Loop + Liraglutide</title>
            <description>Following the first closed loop admission, each participant is initiated on adjunctive once daily liraglutide therapy. They undergo a 3-4 week dose titration period.
Participants are then admitted for a second closed loop admission to assess the combined effects of closed loop control with adjunctive once daily liraglutide therapy.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Nocturnal Glucose Levels</title>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="104" spread="23"/>
                    <measurement group_id="O2" value="113" spread="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Adverse events were recorded in categories with gastrointestinal disorders encompassing nausea, decreased appetite, constipation, bloating and/or diarrhea</desc>
      <group_list>
        <group group_id="E1">
          <title>Closed Loop Only</title>
          <description>Each participant recruited into the study will undergo two inpatient closed loop admissions.
The first admission will be utilizing closed loop control alone, using the Medtronic external Physiological Insulin Delivery (ePID) algorithm. The ePID controller uses a proportional-integral-derivative algorithm modified to include insulin feedback</description>
        </group>
        <group group_id="E2">
          <title>Closed Loop + Liraglutide</title>
          <description>Following the first closed loop admission, each participant is initiated on adjunctive once daily liraglutide therapy. They undergo a 3-4 week dose titration period.
Participants are then admitted for a second closed loop admission to assess the combined effects of closed loop control with adjunctive once daily liraglutide therapy.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>gastrointestinal distress</sub_title>
                <description>nausea, decreased appetite, constipation, bloating, and/or diarrhea</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <description>headache</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Jennifer Sherr</name_or_title>
      <organization>Yale University School of Medicine</organization>
      <phone>203-785-5831</phone>
      <email>jennifer.sherr@yale.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

